Literature DB >> 18680716

The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

Cecilia Gälman1, Tomas Lundåsen, Alexei Kharitonenkov, Holly A Bina, Mats Eriksson, Ingiäld Hafström, Maria Dahlin, Per Amark, Bo Angelin, Mats Rudling.   

Abstract

FGF21 is a critical metabolic regulator, pivotal for fasting adaptation and directly regulated by PPARalpha in rodents. However, the physiological role of FGF21 in man is not yet defined and was investigated in our study. Serum FGF21 varied 250-fold among 76 healthy individuals and did not relate to age, gender, body mass index (BMI), serum lipids, or plasma glucose. FGF21 levels had no diurnal variation and were unrelated to bile acid or cholesterol synthesis. Ketosis induced by a 2 day fast or feeding a ketogenic diet (KD) did not influence FGF21 levels, whereas a 74% increase occurred after 7 days of fasting. Hypertriglyceridemic nondiabetic patients had 2-fold elevated FGF21 levels, which were further increased by 28% during fenofibrate treatment. FGF21 circulates in human plasma and increases by extreme fasting and PPARalpha activation. The wide interindividual variation and the induction of ketogenesis independent of FGF21 levels indicate that the physiological role of FGF21 in humans may differ from that in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18680716     DOI: 10.1016/j.cmet.2008.06.014

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  208 in total

1.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

2.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

Review 3.  Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

Authors:  Matthew J Potthoff; Steven A Kliewer; David J Mangelsdorf
Journal:  Genes Dev       Date:  2012-02-02       Impact factor: 11.361

Review 4.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

5.  FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy.

Authors:  Shenglong Zhu; Yunzhou Wu; Xianlong Ye; Lei Ma; Jianying Qi; Dan Yu; Yuquan Wei; Guangxiao Lin; Guiping Ren; Deshan Li
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

6.  Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes.

Authors:  Rikke Kruse; Sara G Vienberg; Birgitte F Vind; Birgitte Andersen; Kurt Højlund
Journal:  Diabetologia       Date:  2017-07-18       Impact factor: 10.122

7.  Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.

Authors:  Justin A Fletcher; Melissa A Linden; Ryan D Sheldon; Grace M Meers; E Matthew Morris; Anthony Butterfield; James W Perfield; R Scott Rector; John P Thyfault
Journal:  Exp Physiol       Date:  2018-01-16       Impact factor: 2.969

Review 8.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Authors:  Lucas D BonDurant; Matthew J Potthoff
Journal:  Annu Rev Nutr       Date:  2018-05-04       Impact factor: 11.848

9.  Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Authors:  Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2013-05-29       Impact factor: 7.422

Review 10.  Curcumin and dietary polyphenol research: beyond drug discovery.

Authors:  Tian-Ru Jin
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.